Datavant, a fledgling spinoff from Roivant Sciences, is trying to break down information silos that often lead to poorly designed clinical trials.
Envisagenics, which was spun out of Cold Spring Harbor Laboratory, has developed a platform to help drug companies address RNA splicing errors.
Since 2015, the Regeneron Genetics Center has sequenced 250,000 exomes from phenotyped individuals, identifying "human knockouts" and other large-effect mutations.
Qrativ, a joint venture of Mayo Clinic and Nference, seeks new treatments for rare diseases by coupling Mayo research with publicly available genomic data sets.
The companies will share bioinformatics and NGS expertise to speed the identification of diseases, accelerate drug discovery, and find "genomic shields."
TwoXar will work with Stanford's Asian Liver Center to identify and validate computationally-derived drug candidates that target hepatocellular carcinomas.
Cyclica will soon begin testing a commercial version of its services software this summer ahead of a full launch planned for next year.
The partners will generate and analyze disease-specific gene expression data to identify likely drug candidates for rare skin diseases.
Under the terms of the agreement, Insilico Medicine will integrate unspecified data assets and the staff of Belgian bioinformatics company InSilico Screen.
TwoXar will use the funds to expand its engineering and commercial teams and support partnerships focused on drug candidates for metabolic and neurological diseases.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.